AXSM Stock: Axsome Therapeutics, Inc. Stock Price, Analysis & Insights
Get live axsm stock price $182.64, comprehensive Axsome Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time axsm stock data and investment insights.
Loading chart...
Company Overview
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Company Information
- CEO
- Herriot Tabuteau
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 712
Contact Information
- Website
- https://www.axsome.com
- Address
- 22 Cortlandt Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: 0.47) may provide portfolio stability
Business Model & Strategy
Axsome Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Herriot Tabuteau, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Axsome Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 9.2 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Axsome Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Axsome Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Axsome Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Axsome Therapeutics, Inc.
- ⚠Investors should consider how Axsome Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
9.21B
P/E Ratio
-39.11
Beta
0.47
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 9.21B market capitalization
- Trading Volume: 3.02M shares traded today
- Price Range: 52-week range of $79.19 - $184.40
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Axsome Therapeutics, Inc.
Axsome Therapeutics, Inc. (AXSM) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 9.21B, the company represents a significant player in its market. The stock is currently trading at $182.64 with a positivedaily change of 22.75%.
The company's 712 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -39.11, beta of 0.47, and 52-week price range from $79.19 to $184.40when evaluating investment opportunities.
Why Invest in Axsome Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Herriot Tabuteau
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.